Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine

Biological Psychiatry

Volumn 47, Issue 3, 2000, Pages 252-266

  Masellis, Mario ^a   Basile, Vincenzo S ^a   Özdemir, Vural ^a,b   Meltzer, Herbert Y ^c   Macciardi, Fabio M ^a   Kennedy, James L ^a  

^a Centre for Addictions and Mental Health   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Antipsychotic response; Clozapine; Pharmacodynamic; Pharmacogenetic; Pharmacokinetic; Polymorphism

Indexed keywords

CLOZAPINE;

DRUG EFFECT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; METHODOLOGY; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 CYP1A2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALITY; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033959580     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00298-X     Document Type: Review

References (114)

1. Allison D.B. Transmission-disequilibrium tests for quantitative traits. Am J Hum Genet. 60:1997;676-690.
2. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors An autoradiographic analysis in rat brain . Brain Res Bull. 16:1986;517-525.
3. Armstrong S.C., Stephans J.R. Blood clozapine levels elevated by fluvoxamine Potential for side effects and lower clozapine dosage . J Clin Psychiatry. 58:1997;499.
4. Arranz M., Collier D., Sodhi M., et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 346:1995;281-282.
5. Arranz M.J., Collier D.A., Munro J., et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 217:1996;177-178.
6. Arranz M.J., Dawson E., Shaikh S., et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol. 39:1995;417-420.
7. Arranz M.J., Li T., Munro J., et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 8:1998;481-484.
8. Arranz M.J., Munro J., Owen M.J., et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 3:1998;61-66.
9. Arranz M.J., Munro J., Sham P., et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 32:1998;93-99.
10. Ashby C.R., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine A review . Synapse. 24:1996;349-394.
11. Basile V.S., Masellis M., Badri F., et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 21:1999;17-27.
12. Bell R., McLaren A., Galanos J., et al. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 32:1998;567-574.
13. Bender S., Eap C.B. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry. 55:1998;1048-1050.
14. Bertilsson L., Carrillo J.A., Dahl M.L., et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 38:1994;471-473.
15. Byerly M., DeVane L. Pharmacokinetics of clozapine and risperidone A review of recent literature . J Clin Psychopharmacol. 16:1996;177-187.
16. Carrillo J.A., Herraiz A.G., Ramos S.I., et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 18:1998;311-316.
17. Cheng Y.F., Lundberg T., Bondesson U., et al. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol. 34:1988;445-449.
18. Choc M.G., Hsuan F., Honigfeld G., et al. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 7:1990;347-351.
19. Choc M.G., Lehr R.G., Hsuan F., et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 4:1987;402-405.
20. Cohen B.M., Ennulat D.J., Centorrino F., et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl). 141:1999;6-10.
21. Colditz G.A., Burdick E., Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies A commentary . Am J Epidemiol. 142:1995;371-382.
22. Crowe R.R. Candidate genes in psychiatry an epidemiological perspective . Am J Med Genet. 48:1993;74-77.
23. Dains K., Hitzemann B., Hitzemann R. Genetics, neuroleptic response and the organization of cholinergic neurons in the mouse striatum. J Pharmacol Exp Ther. 279:1996;1430-1438.
24. Debouck C., Goodfellow P.N. DNA microarrays in drug discovery and development. Nat Genet. 21:1999;48-50.
25. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 7:1986;177-188.
26. Elston R.C. Linkage and association. Genet Epidemiol. 15:1998;565-576.
27. Farde L., Nordstrom A.L., Wiesel F.A., et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 49:1992;538-544.
28. Frackiewicz E.J., Sramek J.J., Herrera J.M., et al. Ethnicity and antipsychotic response. Ann Pharmacother. 31:1997;1360-1369.
29. Gottesman I.I. Schizophrenia Genesis. The Origins of Madness. 1991;W.H. Freeman, New York.
30. Greenblatt D.J., Harmatz J.S., von Moltke L.L., et al. Pharmacokinetics and pharmacodynamics. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;849-858 Raven, New York.
31. Hasegawa M., Gutierrez-Esteinou R., Way L., et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia Effect of smoking . J Clin Psychopharmacol. 13:1993;383-390.
32. Hiemke C., Weigmann H., Hartter S., et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 14:1994;279-281.
33. Hodge S.E. What association analysis can and cannot tell us about the genetics of complex disease. Am J Med Genet. 54:1994;318-323.
34. Housman D., Ledley F.D. Why pharmacogenomics? Why now? Nat Biotechnol. 16:1998;492-493.
35. Hwu H.G., Hong C.J., Lee Y.L., et al. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry. 44:1998;483-487.
36. Jerling M., Lindstrom L., Bondesson U., et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine Evidence from a therapeutic drug monitoring service . Ther Drug Monit. 16:1994;368-374.
37. Joober R., Benkelfat C., Brisebois K., et al. T102C polymorphism in the 5HT2A gene and schizophrenia Relation to phenotype and drug response variability . J Psychiatry Neurosci. 24:1999;141-146.
38. Kalow W., Tang B.K., Endrenyi L. Hypothesis Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research . Pharmacogenetics. 8:1998;283-289.
39. Kane J.M. Schizophrenia. N Engl J Med. 334:1996;34-41.
40. Kapur S. A new framework for investigating antipsychotic action in humans Lessons from PET imaging . Mol Psychiatry. 3:1998;135-140.
41. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
42. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 156:1999;286-293.
43. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs A critical analysis . Psychopharmacology (Berl). 124:1996;2-34.
44. Kohn Y., Ebstein R.P., HerescoLevy U., et al. Dopamine D4 receptor gene polymorphisms relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects . Eur Neuropsychopharmacol. 7:1997;39-43.
45. Kronig M.H., Munne R.A., Szymanski S., et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 152:1995;179-182.
46. Lappalainen J., Zhang L., Dean M., et al. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 27:1995;274-279.
47. Leboyer M., Bellivier F., Nosten-Bertrand M., et al. Psychiatric genetics search for phenotypes . Trends Neurosci. 21:1998;102-105.
48. Ledley F.D. Can pharmacogenomics make a difference in drug development? Nat Biotechnol. 17:1999;731.
49. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia A rationale and hypothesis . J Clin Psychiatry. 57:1996;68-71.
50. Lieberman J.A. Maximizing clozapine therapy managing side effects . J Clin Psychiatry. 59:1998;38-43.
51. Lieberman J.A., Safferman A.Z., Pollack S., et al. Clinical effects of clozapine in chronic schizophrenia Response to treatment and predictors of outcome . Am J Psychiatry. 151:1994;1744-1752.
52. Lin C.H., Tsai S.J., Yu Y.W., et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 10:1999;57-60.
53. Malhotra A.K., Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry. 45:1999;544-550.
54. Malhotra A.K., Goldman D., Buchanan R.W., et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia A haplotype relative risk study and association with clozapine response . Mol Psychiatry. 3:1998;72-75.
55. Malhotra A.K., Goldman D., Ozaki N., et al. Clozapine response and the 5HT(2C)Cys(23)Ser polymorphism. Neuroreport. 7:1996;2100-2102.
56. Malhotra A.K., Goldman D., Ozaki N., et al. Lack of associaton between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 153:1996;1092-1094.
57. Masellis M., Basile V., Meltzer H.Y., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 19:1998;123-132.
58. 6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res.
59. Masellis M., Paterson A.D., Badri F., et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet. 346:1995;1108.
60. McGuffin P., Owen M.J., Farmer A.E. Genetic basis of schizophrenia. Lancet. 346:1995;678-682.
61. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine The dopamine-serotonin hypothesis of schizophrenia . Psychopharmacology. 99:1989;S18-S27.
62. Meltzer H.Y. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry. 46:1989;672.
63. Meltzer H.Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 55:1994;47-52.
64. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1277-1286 Raven, New York.
65. Meltzer H.Y. Clozapine Is another view valid? Am J Psychiatry. 152:1995;821-825.
66. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 3:1995;64-75.
67. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106-115.
68. Meltzer H.Y., Cola P.A. The pharmacoeconomics of clozapine A review . J Clin Psychiatry. 55:(suppl B):1994;161-165.
69. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 25:1989;390-392.
70. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 25:1999;233-255.
71. Meltzer H.Y., Nash F.J. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev. 43:1991;587-604.
72. Miller D.D. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry. 8:1996;99-109.
73. Miller D.D., Fleming F., Holman T.L., et al. Plasma clozapine concentrations as a predictor of clinical response A follow-up study . J Clin Psychiatry. 55:1994;117-121.
74. Miller R.J., Hiley C.R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 248:1974;596-597.
75. Monteleone P., Tortorella A., Borriello R., et al. Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients A placebo-controlled study . Biol Psychiatry. 45:1999;1606-1611.
76. Nakajima M., Yokoi T., Mizutani M., et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene Effect on the CYP1A2 inducibility in humans . J Biochem (Tokyo). 125:1999;803-808.
77. Nimgaonkar V.L., Zhang X.R., Brar J.S., et al. 5-HT2 receptor gene locus Association with schizophrenia or treatment response not detected . Psychiatr Genet. 6:1996;23-27.
78. Nordstrom A.L., Farde L., Nyberg S., et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentrations A PET study of schizophrenia patients . Am J Psychiatry. 152:1995;1444-1449.
79. Nothen M.M., Rietschel M., Erdmann J., et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet. 346:1995;908-909.
80. Ozdemir V., Masellis M., Basile V.S., et al. Variability in response to clozapine Potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene . CNS Spectrums. 4:1999;30-56.
81. Ozdemir V., Posner P., Collins E.J., et al. CYP1A2 activity predicts clozapine steady state concentration in schizophrenic patients (abstract). Clin Pharmacol Ther. 65:1999;175.
82. Paterson A.D., Sunohara G.A., Kennedy J.L. Dopamine D4 receptor gene Novelty or nonsense? Neuropsychopharmacology. 21:1999;3-16.
83. Perry P.J., Miller D.D., Arndt S.V., et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 148:1991;231-235.
84. Persidis A. Pharmacogenomics and diagnostics. Nat Biotechnol. 16:1998;791-792.
85. Piscitelli S.C., Frazier J.A., McKenna K., et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia association with response . J Clin Psychiatry. 55:1994;94-97.
86. Potkin S.G., Bera R., Gulasekaram B., et al. Plasma clozapine concentrations predict clinical response in treatment- resistant schizophrenia. J Clin Psychiatry. 55:(suppl B):1994;133-136.
87. Rabinowitz D. A transmission disequilibrium test for quantitative trait loci. Hum Hered. 47:1997;342-350.
88. Rao P.A., Pickar D., Gejman P.V., et al. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 51:1994;912-917.
89. Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm. 56:1999;40-50.
90. Rietschel M., Kennedy J.L., Macciardi F.M., et al. Pharmacogenetics in psychosis, the first consensus conference. Schizophr Res. 37:1999;191-196.
91. Rietschel M., Naber D., Fimmers R., et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport. 8:1997;1999-2003.
92. Rietschel M., Naber D., Oberlander H., et al. Efficacy and side-effects of clozapine testing for association with allelic variation in the dopamine D4 receptor gene . Neuropsychopharmacology. 15:1996;491-496.
93. Rowe D.C., Stever C., Gard J.M., et al. The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Genet. 28:1998;215-225.
94. Rowe D.C., Stever C., Giedinghagen L.N., et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry. 3:1998;419-426.
95. Rowland M., Tozer T.N. Clinical Pharmacokinetics. Concepts and Applications, 3rd ed. 1995;Williams & Wilkins, Philadelphia.
96. Sachse C., Brockmoller J., Bauer S., et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 47:1999;445-449.
97. Sanyal S., Van Tol H.H. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J Psychiatr Res. 31:1997;219-232.
98. Sautter F., McDermott B., Garver D. Familial differences between rapid neuroleptic response psychosis and delayed neuroleptic response psychosis. Biol Psychiatry. 33:1993;15-21.
99. Seeman P. Dopamine receptor sequences Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 . Neuropsychopharmacology. 7:1992;261-284.
100. Seeman P., Van Tol H.H. Deriving the therapeutic concentrations for clozapine and haloperidol The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand . Eur J Pharmacol. 291:1995;59-66.
101. Serretti A., Lattuada E., Cusin C., et al. Factor analysis of delusional disorder symptomatology. Compr Psychiatry. 40:1999;143-147.
102. Serretti A., Macciardi F., Smeraldi E. Identification of symptomatologic patterns common to major psychoses Proposal for a phenotype definition . Am J Med Genet. 67:1996;393-400.
103. Shaikh S., Collier D., Kerwin R.W., et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet. 341:1993;116.
104. Shaikh S., Collier D.A., Sham P., et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet (Neuropsychiatr Genet). 60:1995;541-545.
105. Shaikh S., Collier D.A., Sham P.C., et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet. 97:1996;714-719.
106. Snyder S.H., Greenberg D., Yamumura H.I. Antischizophrenic drugs Affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects . J Psychiatr Res. 11:1974;91-95.
107. Sodhi M.S., Arranz M.J., Curtis D., et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. 7:1995;169-172.
108. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 171:1997;109-112.
109. Thomson G. Mapping disease genes Family-based association studies . Am J Hum Genet. 57:1995;487-498.
110. Van Tol H.H., Bunzow J.R., Guan H.C., et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
111. VanderZwaag C., McGee M., McEvoy J.P., et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 153:1996;1579-1584.
112. Vojvoda D., Grimmell K., Sernyak M., et al. Monozygotic twins concordant for response to clozapine. Lancet. 347:1996;61.
113. Wetzel H., Anghelescu I., Szegedi A., et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors Differential effects of fluvoxamine and paroxetine in a prospective study . J Clin Psychopharmacol. 18:1998;2-9.
114. Yu Y.W., Tsai S.J., Lin C.H., et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 10:1999;1231-1233.